Ensysce Biosciences Issues Warrants for 4.36 Million Shares to 3i, LP
Ensysce Biosciences, Inc. has issued a Common Stock Purchase Warrant to 3i, LP, granting the holder the right to purchase up to 4,363,637 shares of the company's common stock. This warrant, issued on April 6, 2026, is exercisable for an eighteen-month period, expiring on October 6, 2027. The company has committed to filing a registration statement for the underlying shares within three business days to ensure they are freely tradable, aiming for effectiveness within 45 days. This issuance is likely part of a broader financing strategy, as indicated by its reference to a Securities Purchase Agreement dated November 13, 2025, and amended on April 2, 2026, providing potential future capital to the company while also implying future dilution for existing shareholders upon exercise.
Key Highlights
- Ensysce Biosciences, Inc. issued a Common Stock Purchase Warrant to 3i, LP.
- The warrant grants the holder the right to purchase up to 4,363,637 shares of common stock.
- The issue date of the warrant is April 6, 2026.
- The warrant is exercisable for an eighteen-month period, expiring at 5:00 p.m. New York City time on October 6, 2027.
- The Company is obligated to file a registration statement for the warrant shares within three business days of the issue date and use best efforts to achieve effectiveness within 45 days.
- The warrant is associated with a Securities Purchase Agreement dated November 13, 2025, which was amended on April 2, 2026.
Price Impact
More from ENSC
More in Equity Offering
One & one Green Technologies Secures $13M in Follow-on Offering from Institutional Investors, with Option for Additional $3M
Linkers Industries Completes Full Exercise of Series B Cashless Warrants, Resulting in 1.52M Class A Shares Outstanding
Annovis Bio Secures $10M Public Offering, Extends Cash Runway to Q2 2027, Funds NDA Submission with AD Phase 3 Trial 75% Enrolled